actinium has been researched along with Neoplasms in 28 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (3.57) | 18.2507 |
2000's | 8 (28.57) | 29.6817 |
2010's | 17 (60.71) | 24.3611 |
2020's | 2 (7.14) | 2.80 |
Authors | Studies |
---|---|
Bruchertseifer, F; Caveliers, V; Covens, P; D'Huyvetter, M; Dekempeneer, Y; Lahoutte, T; Miller, BW; Morgenstern, A; Pruszyński, M; Rodak, M; Sevenois, MB; Wojewódzka, M | 1 |
Bruchertseifer, F; Morgenstern, A | 1 |
Mirzadeh, S | 1 |
Ferrier, MG; Radchenko, V | 1 |
Abbasi, S; Albooyeh, H; Alvandi, M; Farzipour, S; Shaghaghi, Z | 1 |
Allen, BJ | 2 |
Bertalan, T; Bruchertseifer, F; Holleran, T; Josefsson, A; Linz, T; Morgenstern, A; Sempkowski, M; Sofou, S; Zhu, C | 1 |
McDevitt, MR; Sgouros, G; Sofou, S | 1 |
Radchenko, V; Ramogida, CF; Robertson, AKH; Schaffer, P | 1 |
Apostolidis, C; Bruchertseifer, F; Kratochwil, C; Krolicki, L; Morgenstern, A; Sathekge, M | 1 |
Thiele, NA; Wilson, JJ | 1 |
Bednarz, B; Lee, D; Li, M; Schultz, MK | 1 |
Knapp, FFR; Radchenko, V; Schaffer, P | 1 |
Lougheed, T | 1 |
Apostolidis, C; Avila, LA; Dadachova, E; Hanzlik, RP; Iwamoto, T; Liu, K; Morgenstern, A; Sukthankar, P; Tomich, JM; Whitaker, SK | 1 |
Carrasquillo, JA; Cheung, NK; Larson, SM; Press, OW | 1 |
McDevitt, MR; Scheinberg, DA | 2 |
Apostolidis, C; Bruchertseifer, F; Morgenstern, A | 1 |
Fisher, DR; McNamara, BK; Soderquist, CZ | 1 |
Pozzi, OR; Zalutsky, MR | 1 |
Anderson, T; Atcher, R; Nayak, T; Norenberg, J | 1 |
Allen, BJ; Fan Liu, S; Melville, G | 1 |
Beattie, B; Carrasquillo, JA; Chattopadhyay, D; Henke, E; Jaggi, JS; Kappel, BJ; Larson, SM; Nagel, A; Scheinberg, DA; Schwartz, J; Seshan, SV; Sgouros, G; Xiao, J; Zanzonico, P | 1 |
Apostolidis, C; Geerlings, MW; Kaspersen, FM; van der Hout, R | 1 |
Imam, SK | 1 |
Bander, NH; Borchardt, P; Curcio, MJ; Frank, RK; Lai, LT; Ma, D; McDevitt, MR; Miederer, M; Pellegrini, V; Scheinberg, DA; Simon, J; Wu, K | 1 |
12 review(s) available for actinium and Neoplasms
Article | Year |
---|---|
Development of Targeted Alpha Therapy from Bench to Bedside.
Topics: Actinium; Alpha Particles; Bismuth; History, 20th Century; History, 21st Century; Humans; Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy | 2019 |
Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides.
Topics: Actinium; Alpha Particles; Humans; Neoplasms; Radioisotopes; Radiotherapy | 2019 |
An Appendix of Radionuclides Used in Targeted Alpha Therapy.
Topics: Actinium; Alpha Particles; Astatine; Bismuth; Humans; Neoplasms; Radioisotopes; Radiotherapy; Radium; Thorium | 2019 |
Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents.
Topics: Actinium; Alpha Particles; Chelating Agents; Humans; Neoplasms; Radioimmunotherapy; Radium | 2022 |
Targeted and Nontargeted α-Particle Therapies.
Topics: Actinium; Alpha Particles; Animals; Cell Survival; Clinical Trials as Topic; Drug Carriers; Humans; Kinetics; Leukemia; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Neoplasms; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Radium | 2018 |
Development of
Topics: Actinium; Alpha Particles; Humans; Neoplasms; Radiochemistry; Radionuclide Generators; Radiopharmaceuticals | 2018 |
An Overview of Targeted Alpha Therapy with
Topics: Actinium; Alpha Particles; Bismuth; Clinical Trials as Topic; Humans; Neoplasms; Radiochemistry; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals | 2018 |
Radioimmunotherapy of human tumours.
Topics: Actinium; Alpha Particles; Antibodies, Monoclonal; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Molecular Targeted Therapy; Neoplasms; Radioimmunotherapy | 2015 |
Actinium-225 in targeted alpha-particle therapeutic applications.
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Humans; Liposomes; Models, Animal; Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage | 2011 |
Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Topics: Actinium; Aged; Aged, 80 and over; Alpha Particles; Animals; Bismuth; Clinical Trials as Topic; Humans; Mice; Mice, Transgenic; Middle Aged; Neoplasms; Radioisotopes; Radionuclide Generators; Radiopharmaceuticals | 2012 |
Radioimmunotherapy with alpha-particle emitting radionuclides.
Topics: Actinium; Alpha Particles; Antibodies, Monoclonal; Astatine; Bismuth; Humans; Isotopes; Neoplasms; Practice Patterns, Physicians'; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Treatment Outcome | 2004 |
Advancements in cancer therapy with alpha-emitters: a review.
Topics: Actinium; Alpha Particles; Antibodies, Monoclonal; Astatine; Beta Particles; Bismuth; Cell Death; Energy Transfer; Fermium; Humans; Immunoconjugates; Neoplasms; Radioisotopes; Radium; Relative Biological Effectiveness; Terbium | 2001 |
16 other study(ies) available for actinium and Neoplasms
Article | Year |
---|---|
Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
Topics: Actinium; Animals; Cell Line, Tumor; Female; Humans; Mice; Neoplasms; Single-Domain Antibodies; Tissue Distribution; Trastuzumab | 2022 |
A comparative evaluation of Ac225 vs Bi213 as therapeutic radioisotopes for targeted alpha therapy for cancer.
Topics: Actinium; Alpha Particles; Bismuth; DNA Repair; Humans; Neoplasms; Organ Sparing Treatments; Radioisotopes; Radiopharmaceuticals | 2017 |
Alpha-particle radiotherapy: For large solid tumors diffusion trumps targeting.
Topics: Actinium; Alpha Particles; Animals; Antibodies; Cell Death; Cell Line, Tumor; Cell Proliferation; Diffusion; Female; Histones; Humans; Hydrogen-Ion Concentration; Liposomes; Mice, Nude; Neoplasms; Phosphorylation; Spheroids, Cellular; Survival Analysis | 2017 |
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.
Topics: Actinium; Animals; Chelating Agents; Humans; Neoplasms; Radioisotopes; Radiopharmaceuticals | 2018 |
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Topics: Actinium; Alpha Particles; Beta Particles; Bismuth; Dose-Response Relationship, Radiation; Humans; Lead Radioisotopes; Lutetium; Neoplasm Metastasis; Neoplasms; Radioisotopes; Yttrium Radioisotopes | 2018 |
The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
Topics: Actinium; Alpha Particles; Animals; Bismuth; Humans; Neoplasms; Radiochemistry; Radioisotopes; Radionuclide Generators; Radiopharmaceuticals | 2018 |
Isotope once discarded as byproduct shows promise as cancer treatment.
Topics: Actinium; Alpha Particles; Chemical Industry; Compassionate Use Trials; Humans; Neoplasms; Palliative Care | 2018 |
Branched amphiphilic peptide capsules: cellular uptake and retention of encapsulated solutes.
Topics: Actinium; Capsules; Drug Delivery Systems; Humans; Lipid Bilayers; Liposomes; Nanospheres; Neoplasms; Particle Size; Peptides; Radioisotopes; Solutions | 2014 |
Production of high-purity radium-223 from legacy actinium-beryllium neutron sources.
Topics: Actinium; Alpha Particles; Anion Exchange Resins; Beryllium; Humans; Neoplasms; Neutrons; Quality Control; Radioactivity; Radionuclide Generators; Radiopharmaceuticals; Radium | 2012 |
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Topics: Actinium; Alpha Particles; Apoptosis; Beta Particles; Bismuth; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Radiation; Energy Transfer; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Lutetium; Mitosis; Models, Statistical; Neoplasms; Octreotide; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin | 2005 |
A theoretical model for the production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226.
Topics: Actinium; Computer Simulation; Models, Theoretical; Neoplasms; Photons; Radionuclide Generators; Radium | 2006 |
Addendum to: Basic immunology of antibody targeted radiotherapy: in regard to Wong (Int J Radiat Oncol Biol Phys 2006;66: S8-S14).
Topics: Actinium; Antibodies, Monoclonal; Antibody Specificity; Antigens, Neoplasm; Bismuth; Chondroitin Sulfate Proteoglycans; Humans; Membrane Proteins; Neoplasms; Radioimmunotherapy; Radioisotopes | 2007 |
Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.
Topics: Actinium; Animals; Female; Histocompatibility Antigens Class I; Humans; Immunoglobulin G; Immunotherapy; Indium Radioisotopes; Injections, Intravenous; Iodine Radioisotopes; Mice; Neoplasms; Positron-Emission Tomography; Receptors, Fc; Time Factors | 2007 |
The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy.
Topics: Actinium; Alpha Particles; Feasibility Studies; Humans; Neoplasms; Radioimmunotherapy | 1993 |
Tumor therapy with targeted atomic nanogenerators.
Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Female; Half-Life; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Linear Energy Transfer; Lymphoma; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Survival Rate; Tumor Cells, Cultured | 2001 |
Ac-225 and her daughters: the many faces of Shiva.
Topics: Actinium; Alpha Particles; Animals; Beta Particles; Humans; Neoplasms; Radioimmunotherapy; Radioisotopes | 2002 |